PubMed=7670109; DOI=10.1182/blood.V86.7.2708.2708
Cesarman E., Moore P.S., Rao P.H., Inghirami G., Knowles D.M., Chang Y.
In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.
Blood 86:2708-2714(1995)

PubMed=8523568; DOI=10.1128/JVI.70.1.549-558.1996
Moore P.S., Gao S.-J., Dominguez G., Cesarman E., Lungu O., Knowles D.M., Garber R., Pellett P.E., McGeoch D.J., Chang Y.
Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae.
J. Virol. 70:549-558(1996)

PubMed=9766492; DOI=10.1038/sj.leu.2401160
Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.
Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas).
Leukemia 12:1507-1517(1998)

Patent=US5908773
Cesarman E., Arvanitakis L., Knowles D.M., Mesri E.A.
KSHV positive cell lines.
Patent number US5908773, 01-Jun-1999

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005
Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E., Knowles D.M.
Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.
J. Virol. 79:1244-1251(2005)

PubMed=17121789; DOI=10.1128/JVI.01757-06
Burd C.E., Sin S.-H., Dittmer D.P.
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.
J. Virol. 81:1912-1922(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21685375; DOI=10.1182/blood-2010-12-323659
Roy D., Sin S.-H., Damania B., Dittmer D.P.
Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.
Blood 118:E32-E39(2011)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

PubMed=36094314; DOI=10.1128/JVI.00739-22
Ding W.-Y., Wang C., Narita Y., Wang H.-B., Leong M.M.L., Huang A., Liao Y.-F., Liu X.-F., Okuno Y., Kimura H., Gewurz B.E., Teng M.-X., Jin S.-L., Sato Y., Zhao B.
The Epstein-Barr virus enhancer interaction landscapes in virus-associated cancer cell lines.
J. Virol. 96:e0073922.1-e0073922.11(2022)